Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $92,937.92 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 3,236 shares of the stock in a transaction on Monday, April 14th. The stock was sold at an average price of $28.72, for a total transaction of $92,937.92. Following the completion of the transaction, the insider now directly owns 162,898 shares in the company, valued at $4,678,430.56. The trade was a 1.95 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Monday, March 3rd, Soleil Boughton sold 4,151 shares of Hims & Hers Health stock. The stock was sold at an average price of $45.14, for a total transaction of $187,376.14.
• On Monday, March 31st, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.77, for a total value of $89,863.72.
• On Tuesday, February 18th, Soleil Boughton sold 4,152 shares of Hims & Hers Health stock. The stock was sold at an average price of $60.69, for a total transaction of $251,984.88.
• On Monday, February 3rd, Soleil Boughton sold 4,153 shares of Hims & Hers Health stock. The shares were sold at an average price of $35.30, for a total transaction of $146,600.90.
• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.90, for a total value of $1,619,174.70.

Hims & Hers Health Price Performance

HIMS stock traded down $1.32 during mid-day trading on Monday, reaching $25.91. The company had a trading volume of 10,805,858 shares, compared to its average volume of 15,362,967. The firm has a 50 day moving average of $36.85 and a 200 day moving average of $30.85. Hims & Hers Health, Inc. has a 12 month low of $11.20 and a 12 month high of $72.98. The company has a market capitalization of $5.76 billion, a PE ratio of 58.89 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Trading of Hims & Hers Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. Retirement Systems of Alabama purchased a new position in shares of Hims & Hers Health in the first quarter worth $6,876,000. Blue Trust Inc. lifted its position in Hims & Hers Health by 119.8% during the 1st quarter. Blue Trust Inc. now owns 1,923 shares of the company's stock worth $57,000 after acquiring an additional 1,048 shares during the period. Rakuten Securities Inc. grew its stake in Hims & Hers Health by 282.5% during the 1st quarter. Rakuten Securities Inc. now owns 18,049 shares of the company's stock valued at $533,000 after purchasing an additional 13,330 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in shares of Hims & Hers Health in the first quarter valued at about $132,000. Finally, QRG Capital Management Inc. raised its stake in shares of Hims & Hers Health by 2.8% in the first quarter. QRG Capital Management Inc. now owns 187,755 shares of the company's stock worth $5,548,000 after purchasing an additional 5,168 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on HIMS shares. Morgan Stanley lowered shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and lifted their target price for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Needham & Company LLC increased their target price on Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a research report on Tuesday, February 25th. Piper Sandler lifted their price target on Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a research report on Tuesday, February 25th. Truist Financial lowered their price objective on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research report on Thursday, April 10th. Finally, Bank of America increased their price target on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a research note on Tuesday, March 18th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $38.25.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.